enGene interim CMO William Grossman acquires common shares worth $10,050.94

ENGN•2026-09-24

Interim Chief Medical Officer William Grossman bought 5,102 enGene Therapeutics common shares at $1.97 each, bringing his directly held stake to 5,102 shares.

1. Share purchase

William Grossman, enGene Therapeutics’ interim chief medical officer, bought 5,102 common shares at $1.97 each. His post-transaction stake was 5,102 shares held directly.

Sources

enGene interim CMO William Grossman acquires common shares worth $10,050.94

Sec

enGene interim CMO William Grossman acquires common shares worth $10,050.94

1. Share purchase

Related News

Infobird FY26 H1 net loss widens to USD 15.83 million; revenue falls 45.85% to USD 1.86 million

YYForce FY26 H1 net loss narrows 13.8% to US$7.06 million; revenue rises 26.8% to US$32.7 million

ONE Group names Caroline O'Mahony Baker chief operating officer

Sources

enGene interim CMO William Grossman acquires common shares worth $10,050.94

Durable Capital Partners buys $7.1 million of Goosehead Insurance shares

Encompass Health to open first small-format rehab hospital in Conroe, Texas